Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.55 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.55 |
| ▸ | CYP8B1 | Q9UNU6 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramiconazole SCHEMBL3048310 | 1.00 | CYP3A4 (0.55) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| Pramiconazole SCHEMBL6152243 | 0.99 | CYP3A4 (0.55) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| Pramiconazole SCHEMBL6152244 | 0.99 | CYP3A4 (0.55) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL6151936 | 0.94 | CYP3A4 (0.56) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL6151935 | 0.94 | CYP3A4 (0.56) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL17832624 | 0.90 | CYP3A4 (0.43) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL17824324 | 0.90 | CYP3A4 (0.43) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL19730470 | 0.90 | CYP3A4 (0.43) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL29726392 | 0.90 | CYP3A4 (0.51) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL9254879 | 0.90 | CYP3A4 (0.54) | CYP3A4ABCG2CYP17A1CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214300-B1 | RATE-CONTROLLED PARTICLES | ABBOTT GMBH & CO KG (DE) | 2003-09-03 | — | — | EP | claimed |
| WO-2001001955-A1 | NASAL FORMULATION OF AN ANTIFUNGAL | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-11 | — | — | WO | claimed |
| US-9192577-B2 | Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-9028876-B2 | Rate-controlled particles | JANSSEN R&D IRELAND (IE) | 2015-05-12 | — | — | US | disclosed |
| US-20130237705-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | PETERSON JOHN R (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130225817-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | PETERSON JOHN R (US) | 2013-08-29 | — | — | US | disclosed |
| US-8431699-B2 | Method for manufacture of 2-oxoimidazolidines | Vertichem Corporation (CA) | 2013-04-30 | — | — | US | disclosed |
| US-20120172364-A1 | RATE-CONTROLLED PARTICLES | JANSSEN R&D IRELAND (IE) | 2012-07-05 | — | — | US | disclosed |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | THESIS CHEMISTRY, LLC (US) | 2010-09-02 | — | — | US | disclosed |
| US-20090148531-A1 | RATE-CONTROLLED PARTICLES | JANSSEN R&D IRELAND (IE) | 2009-06-11 | — | — | US | disclosed |
| US-20060078609-A1 | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
| EP-1068200-B1 | 2,4,4-TRISUBSTITUTED-1,3-DIOXOLANE ANTIFUNGALS | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004050068-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-17 | — | — | WO | disclosed |
| EP-1214300-B1 | RATE-CONTROLLED PARTICLES | ABBOTT GMBH & CO KG (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-0998304-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC DRUG, A CYCLODEXTRIN, A POLYMER AND AN ACID | JANSSEN PHARMACEUTICA NV (BE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020150616-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLODEXTRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-17 | — | — | US | disclosed |
| US-6387906-B1 | DERMATOPHYTES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-14 | — | — | US | disclosed |
| EP-1068200-A1 | 2,4,4-TRISUBSTITUTED-1,3-DIOXOLANE ANTIFUNGALS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-17 | — | — | EP | disclosed |
| WO-2001001955-A1 | NASAL FORMULATION OF AN ANTIFUNGAL | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-11 | — | — | WO | disclosed |
| WO-1999002523-A1 | 2,4,4-TRISUBSTITUTED-1,3-DIOXOLANE ANTIFUNGALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060078609-A1 | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water soluble and respectively base | SLC10A1, SLC7A1, SLC26A4 | CYP3A4 578/4885ABCG2 13/4885CYP17A1 968/4885 |
| US-20130237705-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | ODC1, NISCH, IMPDH2 | CYP3A4 6/4885ABCG2 2855/4885CYP17A1 1978/4885 |
| US-20090148531-A1 | RATE-CONTROLLED PARTICLES | APOB, CCNB2, CYP2C19 | CYP3A4 30/4885ABCG2 181/4885CYP17A1 199/4885 |
| US-20120172364-A1 | RATE-CONTROLLED PARTICLES | APOB, CCNB2, CYP2C19 | CYP3A4 30/4885ABCG2 181/4885CYP17A1 199/4885 |
| US-20100222588-A1 | Method for Manufacture of 2-Oxoimidazolidines | ODC1, CBR3, CBR1 | CYP3A4 35/4885ABCG2 2293/4885CYP17A1 1186/4885 |
| US-20130225817-A1 | METHOD FOR MANUFACTURE OF 2-OXOIMIDAZOLIDINES | ODC1, NISCH, IMPDH2 | CYP3A4 6/4885ABCG2 2855/4885CYP17A1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.